I mean they could go alone, but it’s incredibly risky. The PRV would likely go for 80-100M USD which would cover their P2B EMA + Dual FDA preclin/clin trials, but likely would dry up and not cover the later phase 2 trials for the FDA. I doubt ANP management want to try and tackle these pipelines by themselves, but I could be wrong.0
I mean they could go alone, but it’s incredibly risky. The PRV...
-
- There are more pages in this discussion • 1,586 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.8¢ |
Change
-0.002(2.50%) |
Mkt cap ! $70.32M | |||
| Open | High | Low | Value | Volume |
| 7.6¢ | 7.8¢ | 7.5¢ | $32.58K | 429.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 253224 | 7.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.0¢ | 253231 | 2 |
View Market Depth
| Last trade - 14.56pm 22/07/2024 (20 minute delay) ? |
| PER (ASX) Chart |